{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:44:38Z","timestamp":1792813478889,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002460","name":"Chung-Ang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002460","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.prnil.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:54:41Z","timestamp":1747223681000},"page":"191-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oncologic outcomes of salvage radiotherapy and lymphadenectomy for positron emission tomography\u2013positive lymph nodes in biochemical recurrence: A systematic review to inform treatment decisions"],"prefix":"10.1016","volume":"13","author":[{"given":"Yun-Jung","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungchan","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hyun","family":"Tae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung Un","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joongwon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4615-0966","authenticated-orcid":false,"given":"Se Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prnil.2025.05.002_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prnil.2025.05.002_bib2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.prnil.2025.05.002_bib3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2025.05.002_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.prnil.2022.11.001","article-title":"Detection of recurrence sites using (18)F-fluorocholine PET\/CT in prostate cancer patients with PSA failure","volume":"11","author":"Kim","year":"2023","journal-title":"Prostate Int"},{"key":"10.1016\/j.prnil.2025.05.002_bib5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.19.02757","article-title":"Optimum imaging strategies for advanced prostate cancer: ASCO guideline","volume":"38","author":"Trabulsi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib6","article-title":"The diagnostic role of (18)F-choline, (18)F-fluciclovine and (18)F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.redii.2022.100021","article-title":"18 F-PSMA-1007PET\/CT in patients with biochemical recurrence after radical prostatectomy: diagnostic performance and impact on treatment management","volume":"5","author":"Jiang","year":"2023","journal-title":"Research in Diagnostic and Interventional Imaging"},{"key":"10.1016\/j.prnil.2025.05.002_bib8","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1007\/s00330-022-08802-7","article-title":"Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis","volume":"32","author":"Ma","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.prnil.2025.05.002_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.prnil.2025.05.002_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst Rev"},{"key":"10.1016\/j.prnil.2025.05.002_bib11","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses","author":"Ga Wells","year":"2000"},{"key":"10.1016\/j.prnil.2025.05.002_bib12","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2011"},{"key":"10.1016\/j.prnil.2025.05.002_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/bco2.151","article-title":"Cribriform pattern disease over-represented in pelvic lymph node metastases identified on (68)GA PSMA-PET\/CT","volume":"3","author":"Bolton","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.prnil.2025.05.002_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/bco2.182","article-title":"Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer","volume":"4","author":"Bravi","year":"2023","journal-title":"BJUI Compass"},{"key":"10.1016\/j.prnil.2025.05.002_bib15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2021.02.031","article-title":"Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis","volume":"80","author":"Glicksman","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2025.05.002_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.juro.2014.08.082","article-title":"Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography\/computerized tomography","volume":"193","author":"Karnes","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.prnil.2025.05.002_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","article-title":"Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen-radioguided surgery","volume":"83","author":"Knipper","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2025.05.002_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.708595","article-title":"Patient-reported and oncological outcomes of salvage therapies for PSMA-positive nodal recurrent prostate cancer: real-life experiences and implications for future trial design","volume":"11","author":"Kretschmer","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00066-014-0763-5","article-title":"Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only","volume":"191","author":"Rischke","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.prnil.2025.05.002_bib20","first-page":"E545","article-title":"Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease","volume":"15","author":"Bobrowski","year":"2021","journal-title":"Cuaj-Canadian Urological Association Journal"},{"key":"10.1016\/j.prnil.2025.05.002_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00781","article-title":"Comparison of peri-operative and early oncological outcomes of robot-assisted vs. Open salvage lymph node dissection in recurrent prostate cancer","volume":"9","author":"Devos","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2967\/jnumed.119.235374","article-title":"Mapping prostate cancer lesions before and after unsuccessful salvage lymph node dissection using repeat PSMA PET","volume":"61","author":"Farolfi","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prnil.2025.05.002_bib23","doi-asserted-by":"crossref","first-page":"84180","DOI":"10.18632\/oncotarget.21118","article-title":"Salvage lymph node dissection after Ga-68-PSMA or F-18-FEC PET\/CT for nodal recurrence in prostate cancer patients","volume":"8","author":"Herlemann","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prnil.2025.05.002_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12894-016-0173-3","article-title":"Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection","volume":"16","author":"Osmonov","year":"2016","journal-title":"BMC Urol"},{"key":"10.1016\/j.prnil.2025.05.002_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bju.13713","article-title":"Value of In-111-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up","volume":"120","author":"Rauscher","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.prnil.2025.05.002_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000144059","article-title":"C-11 choline PET\/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer","volume":"81","author":"Rinnab","year":"2008","journal-title":"Urol Int"},{"key":"10.1016\/j.prnil.2025.05.002_bib27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2016.01.008","article-title":"Mid-term outcomes following salvage lymph node dissection for prostate cancer nodal recurrence status post-radical prostatectomy","volume":"2","author":"Zattoni","year":"2016","journal-title":"European Urology Focus"},{"key":"10.1016\/j.prnil.2025.05.002_bib28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00066-020-01605-z","article-title":"PSMA-positive nodal recurrence in prostate cancer : salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis","volume":"196","author":"Schmidt-Hegemann","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.prnil.2025.05.002_bib29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41391-020-00307-y","article-title":"Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience","volume":"24","author":"Boeri","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.prnil.2025.05.002_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20010537","article-title":"The utility of 68Ga-PSMA PET\/CT in decisions regarding administering salvage radiotherapy to men with prostate cancer","volume":"20","author":"Ben Shimol","year":"2022","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.prnil.2025.05.002_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8120536","article-title":"(68)Ga-PSMA-11 PET\/CT-Guided stereotactic body radiation therapy retreatment in prostate cancer patients with PSA failure after salvage radiotherapy","volume":"8","author":"Caroli","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.prnil.2025.05.002_bib32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2014.05.050","article-title":"18F-choline positron emission tomography\/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients","volume":"90","author":"D'Angelillo","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prnil.2025.05.002_bib33","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2967\/jnumed.117.196683","article-title":"Treatment outcomes from (68)Ga-PSMA PET\/CT-Informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET","volume":"58","author":"Emmett","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prnil.2025.05.002_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euo.2021.10.002","article-title":"Toxicity and efficacy of local ablative, image-guided radiotherapy in gallium-68 prostate-specific membrane antigen targeted positron emission tomography-staged, castration-sensitive oligometastatic prostate cancer: the OLI-P phase 2 clinical trial","volume":"5","author":"H\u00f6lscher","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib35","article-title":"Salvage involved-field and extended-field radiation therapy in positron emission tomography-positive nodal recurrent prostate cancer: outcomes and patterns of failure","volume":"8","author":"P\u00eatre","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109678","article-title":"Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study","volume":"184","author":"Scharl","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib37","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ijrobp.2022.04.048","article-title":"Metastasis-free survival and patterns of distant metastatic disease after prostate-specific membrane antigen positron emission tomography (PSMA-PET)-Guided salvage radiation therapy in recurrent or persistent prostate cancer after prostatectomy","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prnil.2025.05.002_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113395","article-title":"Outcome after 68Ga-PSMA-11 versus choline PET-based salvage radiotherapy in patients with biochemical recurrence of prostate cancer: a matched-pair analysis","volume":"12","author":"Schmidt Hegemann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prnil.2025.05.002_bib39","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1007\/s00259-020-04708-y","article-title":"Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study","volume":"47","author":"Schmidt-Hegemann","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.prnil.2025.05.002_bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2967\/jnumed.118.212563","article-title":"Outcome after PSMA PET\/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis","volume":"60","author":"Schmidt-Hegemann","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prnil.2025.05.002_bib41","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1007\/s00259-023-06195-3","article-title":"Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy","volume":"50","author":"Spohn","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.prnil.2025.05.002_bib42","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.prnil.2025.05.002_bib43","first-page":"238","article-title":"Salvage radiotherapy in prostate cancer patients. Planning, treatment response and prognosis using C-11-choline PET\/CT","volume":"35","author":"Garcia","year":"2016","journal-title":"Rev Espa\u00f1ola Med Nucl Imagen Mol"},{"key":"10.1016\/j.prnil.2025.05.002_bib44","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.21873\/anticanres.11444","article-title":"Ga-68-PSMA ligand PET\/CT-based radiotherapy for lymph node relapse of prostate cancer after primary therapy delays initiation of systemic therapy","volume":"37","author":"Henkenberens","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.prnil.2025.05.002_bib45","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.2967\/jnumed.115.163741","article-title":"Radiation treatment of lymph node recurrence from prostate cancer: is C-11-Choline PET\/CT predictive of survival outcomes?","volume":"56","author":"Incerti","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prnil.2025.05.002_bib46","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1007\/s12094-020-02364-0","article-title":"Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer","volume":"22","author":"Ingrosso","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib47","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1097\/RLU.0000000000004590","article-title":"Impact of F-18-Fluciclovine PET\/CT findings on failure-free survival in biochemical recurrence of prostate cancer following salvage radiation therapy","volume":"48","author":"Lawal","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.prnil.2025.05.002_bib48","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-019-0515-z","article-title":"Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience","volume":"19","author":"Oehler","year":"2019","journal-title":"BMC Urol"},{"key":"10.1016\/j.prnil.2025.05.002_bib49","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00259-021-05557-z","article-title":"Outcome after PSMA-PET\/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy","volume":"49","author":"Rogowski","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.prnil.2025.05.002_bib50","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1080\/0284186X.2021.1955970","article-title":"Progression-free survival in patients with Ga-68-PSMA-PET-directed SBRT for lymph node oligometastases","volume":"60","author":"Werensteijn-Honingh","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of (68)Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prnil.2025.05.002_bib52","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib53","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.prnil.2025.05.002_bib54","article-title":"The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients","author":"Bauckneht","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.prnil.2025.05.002_bib55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/JU.0000000000003518","article-title":"A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer","volume":"210","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.prnil.2025.05.002_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","article-title":"(68)Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng\/ml. Efficacy and impact on treatment strategy","volume":"46","author":"Farolfi","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.prnil.2025.05.002_bib57","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","article-title":"Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib58","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prnil.2025.05.002_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euf.2019.06.004","article-title":"Biochemical recurrence in prostate cancer: the European association of Urology prostate cancer guidelines panel recommendations","volume":"6","author":"Van den Broeck","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.prnil.2025.05.002_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112926","article-title":"Peering through the PSMA PET lens: the role of the European association of Urology biochemical recurrence risk groups after radical prostatectomy","volume":"15","author":"Leplat","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prnil.2025.05.002_bib61","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bju.15664","article-title":"The clinical characteristics of patients with primary non-prostate-specific membrane antigen-expressing prostate cancer on preoperative positron emission tomography\/computed tomography","volume":"129","author":"Veerman","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.prnil.2025.05.002_bib62","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","article-title":"Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients","volume":"47","author":"Vaz","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.prnil.2025.05.002_bib63","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1038\/s41598-018-22594-1","article-title":"PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis","volume":"8","author":"Bravaccini","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.prnil.2025.05.002_bib64","doi-asserted-by":"crossref","first-page":"449","DOI":"10.21873\/anticanres.16181","article-title":"Assessment of prostate carcinoma aggressiveness: relation to (68)Ga-PSMA-11-PET\/MRI and Gleason score","volume":"43","author":"Ferda","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.prnil.2025.05.002_bib65","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00259-020-04945-1","article-title":"False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial","volume":"48","author":"Fendler","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.prnil.2025.05.002_bib66","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prnil.2025.05.002_bib67","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4111\/icu.20240229","article-title":"Prostate cancer theragnostics biomarkers: an update","volume":"65","author":"Kumar","year":"2024","journal-title":"Investig Clin Urol"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S228788822500042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S228788822500042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T06:25:41Z","timestamp":1765434341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S228788822500042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S228788822500042X"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2025.05.002","relation":{},"ISSN":["2287-8882"],"issn-type":[{"value":"2287-8882","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncologic outcomes of salvage radiotherapy and lymphadenectomy for positron emission tomography\u2013positive lymph nodes in biochemical recurrence: A systematic review to inform treatment decisions","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Asian Pacific Prostate Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}